^
    6d
    Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 19 | Trial completion date: Mar 2043 --> Jul 2040 | Trial primary completion date: Mar 2027 --> Aug 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    22d
    P-BCMA-ALLO1-001: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=275, Recruiting, Poseida Therapeutics, Inc. | Trial completion date: Dec 2039 --> Mar 2042 | Trial primary completion date: Dec 2027 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    RG6538 • rimiducid (AP1903)
    1m
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2040 --> Sep 2037 | Trial primary completion date: Dec 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)
    2ms
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=54 --> 17 | Trial completion date: Apr 2041 --> Aug 2040 | Trial primary completion date: Apr 2026 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)
    3ms
    Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    5ms
    Side_by_Cide: T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. (clinicaltrials.gov)
    P1/2, N=2, Terminated, Centre Hospitalier Universitaire de Besancon | N=12 --> 2 | Unknown status --> Terminated; not enough recruitment because of new therapeutic alternatives
    Enrollment change • Trial termination
    |
    rimiducid (AP1903)
    5ms
    T-Cell Therapy for Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=186, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    HER-2 negative
    |
    cyclophosphamide • rimiducid (AP1903)
    7ms
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=162, Not yet recruiting, Genentech, Inc.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • RG6540 • rimiducid (AP1903)
    9ms
    P-MUC1C-ALLO1-001: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects with Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=180, Active, not recruiting, Poseida Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    P-MUC1C-ALLO1 • rimiducid (AP1903)
    10ms
    P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) (clinicaltrials.gov)
    P1, N=40, Terminated, Poseida Therapeutics, Inc. | N=60 --> 40 | Trial completion date: Sep 2036 --> Sep 2024 | Active, not recruiting --> Terminated; Study closed
    Enrollment change • Trial completion date • Trial termination
    |
    rimiducid (AP1903)
    11ms
    PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. (PubMed, Nat Commun)
    Rimiducid increased circulating inflammatory cytokines/chemokines consistent with GoCAR-T® cell activation. These results suggest that pharmacological activation of GoCAR-T® cells is feasible and may offer a promising avenue to control chimeric antigen receptor-T cell activity with continued dose-optimization to improve tolerability.
    P1 data • Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD40 (CD40 Molecule) • PSCA (Prostate Stem Cell Antigen 2)
    |
    BPX-601 • rimiducid (AP1903)
    12ms
    Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) (clinicaltrials.gov)
    P1, N=42, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Minimal residual disease
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • TROP2-CAR-NK • rimiducid (AP1903)